Clinical and prognostic significance of Yes-associated protein in colorectal cancer

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2169-2174

  Wang, Yan ^a   Xie, Chengyao ^a   Li, Qingchang ^a   Xu, Ke ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Prognosis; Yes associated protein; catenin

Indexed keywords

BETA CATENIN; CYCLIN D1; ONCOPROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; YES ASSOCIATED PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

EID: 84881474686     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0751-x     Document Type: Article

References (34)

1. Zhao B et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24(9):862-74.
2. Dong J et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120-33.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
4. Huang J et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell. 2005;122(3):421-34.
5. Wu S et al. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114(4):445-56.
6. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell. 2006;124(2):267-73.
7. Pan D. Hippo signaling in organ size control. Genes Dev. 2007;21(8):886-97.
8. Zhao B et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747-61.
9. Overholtzer M et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006;103(33):12405-10.
10. Zender L et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253-67.
11. Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem. 2001;276(17):14514-23.
12. Howell M, Borchers C, Milgram SL. Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription. J Biol Chem. 2004;279(25):26300-6.
13. Komuro A et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 2003;278(35):33334-41.
14. Strano S et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell. 2005;18(4):447-59.
15. Strano S et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem. 2001;276(18):15164-73.
16. Yagi R et al. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18(9):2551-62.
17. Zaidi SK et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 2004;23(4):790-9.
18. Zhao B et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-71.
19. Baldwin C et al. Multiple microalterations detected at high frequency in oral cancer. Cancer Res. 2005;65(17):7561-7.
20. Fernandez LA et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23(23):2729-41.
21. Modena P et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24(33):5223-33.
22. Snijders AM et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24(26):4232-42.
23. Steinhardt AA et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008;39(11):1582-9.
24. Wang Y et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010;101(5):1279-85.
25. Xu MZ et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115(19):4576-85.
26. Camargo FD et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17(23):2054-60.
27. Jemal A, et al. Cancer statistics. CA Cancer J Clin.2010.
28. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387-98.
29. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle. 2012;11(6):1090-6.
30. Zhou D et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A. 2011;108(49):E1312-20.
31. Konsavage Jr WM et al. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 2012;287(15):11730-9.
32. Ogino S et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009;15(13):4431-8.
33. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev. 2008;22(23):3320-34.
34. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-80.